Personalized cardiovascular disease prevention by applying individualized prediction of treatment effects
- PMID: 24513790
- DOI: 10.1093/eurheartj/ehu004
Personalized cardiovascular disease prevention by applying individualized prediction of treatment effects
Abstract
Large-scale randomized clinical trials have established the efficacy of cholesterol-lowering, blood pressure-lowering, and anti-platelet therapy to prevent cardiovascular diseases. A challenge for clinicians is to apply group-level evidence from these trials to individual patients. Trials typically report a single treatment effect estimate which is the average effect of all participants, comprising patients who respond poorly, intermediately, and well. Clinicians would preferably make patient-tailored treatment decisions. Therefore, one would require an estimate of an individual patient's response to therapy. Although not yet widely recognized, trials contain this type of information. In this paper, we show how available information from landmark trials can be translated to an individual 'treatment score' through the use of multivariable therapeutic prediction models. These models provide an individual estimate of the absolute risk reduction in cardiovascular events given the specific combination of multiple clinical characteristics of a patient under care. Based on this individualized treatment estimate and metrics such as the individual number-needed-to-treat, clinicians together with their patients can decide whether drug treatment or what treatment intensity is worthwhile. Selective treatment of those who can anticipate the greatest benefit and the least harm on an individualized basis could reduce the number of unnecessary treatments and healthcare costs beyond that currently achievable by subgroup analyses based on single patient characteristics.
Keywords: Individualized cardiovascular medicine; Net benefit; Prediction of treatment effect.
Similar articles
-
Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?Adv Ther. 2009 May;26(5):469-87. doi: 10.1007/s12325-009-0025-6. Epub 2009 May 14. Adv Ther. 2009. PMID: 19444394 Review.
-
Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?Am J Cardiol. 2006 Jan 16;97(2A):33A-41A. doi: 10.1016/j.amjcard.2005.11.014. Epub 2005 Dec 1. Am J Cardiol. 2006. PMID: 16442935 Review.
-
Impact of rosuvastatin use on costs and outcomes in patients at high risk for cardiovascular disease in US managed care and medicare populations: A data analysis.Clin Ther. 2006 Sep;28(9):1425-42. doi: 10.1016/j.clinthera.2006.09.019. Clin Ther. 2006. PMID: 17062315
-
Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal.Arch Intern Med. 2010 Jun 28;170(12):1032-6. doi: 10.1001/archinternmed.2010.184. Arch Intern Med. 2010. PMID: 20585068 Review.
-
The numbers are in: statins for the primary prevention of cardiovascular disease in women.Circulation. 2010 Mar 9;121(9):1063-5. doi: 10.1161/CIR.0b013e3181d731c6. Epub 2010 Feb 22. Circulation. 2010. PMID: 20176993 No abstract available.
Cited by
-
Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes.Diabetologia. 2016 Dec;59(12):2603-2612. doi: 10.1007/s00125-016-4082-5. Epub 2016 Sep 1. Diabetologia. 2016. PMID: 27586250 Free PMC article.
-
Primary prevention of cardiovascular disease: The past, present, and future of blood pressure- and cholesterol-lowering treatments.PLoS Med. 2018 Mar 20;15(3):e1002539. doi: 10.1371/journal.pmed.1002539. eCollection 2018 Mar. PLoS Med. 2018. PMID: 29558473 Free PMC article.
-
Patient phenotyping in clinical trials of chronic pain treatments: IMMPACT recommendations.Pain. 2016 Sep;157(9):1851-1871. doi: 10.1097/j.pain.0000000000000602. Pain. 2016. PMID: 27152687 Free PMC article. Review.
-
Translating clinical trial results into personalized recommendations by considering multiple outcomes and subjective views.NPJ Digit Med. 2019 Aug 21;2:81. doi: 10.1038/s41746-019-0156-3. eCollection 2019. NPJ Digit Med. 2019. PMID: 31453376 Free PMC article.
-
Personalized Statin Therapy and Coronary Atherosclerotic Plaque Burden in Asymptomatic Low/Intermediate-Risk Individuals.Cardiorenal Med. 2018;8(2):140-150. doi: 10.1159/000487205. Epub 2018 Mar 26. Cardiorenal Med. 2018. PMID: 29617001 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources